Indaptus Therapeutics, Inc. 8-K

What Happened

• Indaptus Therapeutics filed an 8-K on June 5, 2026, announcing that directors David E. Lazar and Avraham Ben‑Tzvi resigned from the Board and all committee positions effective June 5, 2026. Separately, Walt A. Linscott, Esq. resigned as Chief Operating Officer effective June 1, 2026, and will continue working for the company under a consulting agreement dated June 1, 2026. The filings state these departures were not due to any disagreement with the company’s operations, policies, or practices.

Key Details

• Two directors resigned: David E. Lazar and Avraham Ben‑Tzvi (effective June 5, 2026).
• COO change: Walt A. Linscott resigned as COO (effective June 1, 2026) and immediately entered a consulting agreement dated June 1, 2026.
• Company note: Resignations were explicitly stated not to result from any disagreement with the company.
• Board comment: The Board thanked Mr. Lazar and Mr. Ben‑Tzvi and indicated it will continue working with Mr. Linscott in a strategic advisory role.

Why It Matters

• Governance and leadership changes can affect investor confidence and oversight; two board departures reduce the current board membership until replacements are named.
• The COO’s shift to a consultant role suggests continuity in operational advising but signals a change in day‑to‑day management.
• Investors should watch for follow-up filings naming new directors or an interim COO, and any statements about impacts to strategy, operations, or clinical/development timelines.